drugset
drugset / Trial / NCT05843305

A Study of BPI-452080 in Subjects With Solid Tumors

NCT05843305 ↗

Phase 1 Unknown 87 enrolled Betta Pharmaceuticals Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This open-label Phase 1 study will evaluate the efficacy and safety of BPI-452080 in patients with Solid Tumors

Timeline

Start
2023-04-28
Primary completion
2025-03-25
Completion
2025-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BPI-452080 Unknown — Oral

Indications

renal cell carcinoma von Hippel-Lindau disease